Phase I/II 90 Y-Zevalin (yttrium-90 ibritumomab tiuxetan, IDEC-Y2B8) radioimmunotherapy dosimetry results in relapsed or refractory non-Hodgkin's lymphoma von Wiseman, Gregory A., White, Christine A., Stabin, Michael, Dunn, William L., Erwin, William, Dahlbom, Magnus, Raubitschek, Andrew, Karvelis, Kastytis, Schultheiss, Timothy, Witzig, Thomas E., Belanger, Richard, Spies, Stewart, Silverman, Daniel H. S., Berlfein, Judy R., Ding, Eric, Grillo-López, Antonio J.

Volltext

Phase I/II 90Y-Zevalin (yttrium-90 ibritumomab tiuxetan, IDEC-Y2B8) radioimmunotherapy dosimetry results in relapsed or refractory non-Hodgkin's lymphoma von Wiseman, Gregory A, White, Christine A, Stabin, Michael, Dunn, William L, Erwin, William, Dahlbom, Magnus, Raubitschek, Andrew, Karvelis, Kastytis, Schultheiss, Timothy, Witzig, Thomas E, Belanger, Richard, Spies, Stewart, Silverman, Daniel H S, Berlfein, Judy R, Ding, Eric, Grillo-lópez, Antonio J

Volltext

Prolonged Clinical and Molecular Remission in Patients With Low-Grade or Follicular Non-Hodgkin's Lymphoma Treated With Rituximab Plus CHOP Chemotherapy: 9-Year Follow-Up von CZUCZMAN, Myron S, WEAVER, Robin, ALKUZWENY, Baha, BERLFEIN, Judy, GRILLO-LOPEZ, Antonio J

Volltext